EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudieOpen Access · CC BY-NC 4.0

Comparative analysis of recurrence rates between intravesical gemcitabine and bacillus Calmette–Guérin induction therapy following transurethral resection of bladder tumors in patients with intermediate- and high-risk bladder cancer: A retrospective multicenter study

Joongwon Choi iD, Kyung Hwan Kim iD, Hyung Suk Kim iD, Hyun Sik Yoon iD, Jung Hoon Kim iD, Jin Wook Kim iD, Yong Seong Lee iD, Se Young Choi iD, In Ho Chang iD, Young Hwii Ko iD, Wan Song iD, Byong Chang Jeong iD und 1 weitere

Investigative and Clinical Urology · 2024 · 65 (3) · 248

DOI: 10.4111/icu.20230313 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Investigative and Clinical Urology, 2024. Verfasst von Joongwon Choi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine, Gwangmyeong, Korea. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Gemcitabine, Deoxycytidine, BCG Vaccine. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsGemcitabineDeoxycytidineBCG VaccineNeoplasm Recurrence, LocalAntimetabolites, AntineoplasticAdjuvants, ImmunologicHumansRetrospective StudiesMaleFemaleAdministration, IntravesicalAgedMiddle AgedCystectomyRisk AssessmentUrethra

Stichwörter der Autor:innen

Bladder neoplasmsGemcitabineMycobacterium bovis

Substanzen

GemcitabineDeoxycytidineBCG VaccineAntimetabolites, AntineoplasticAdjuvants, Immunologic

Autor:innen und Institutionen

  • Department of Urology, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine, Gwangmyeong, Korea.
  • Department of Urology, Pusan National University Hospital, School of Medicine, Pusan National University, Busan, Korea.
  • Department of Urology, Dongguk University Ilsan Medical Center, Dongguk University College of Medicine, Goyang, Korea.
  • Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea.
  • Department of Urology, Yeungnam University College of Medicine, Daegu, Korea.
  • Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

ORCID-Profile: Joongwon Choi, Kyung Hwan Kim, Hyung Suk Kim, Hyun Sik Yoon, Jung Hoon Kim, Jin Wook Kim, Yong Seong Lee, Se Young Choi, In Ho Chang, Young Hwii Ko, Wan Song, Byong Chang Jeong, Jong Kil Nam

Zitieren

APA

Choi, J., Kim, K. H., Kim, H. S., Yoon, H. S., Kim, J. H., Kim, J. W., Lee, Y. S., Choi, S. Y., Chang, I. H., Ko, Y. H., Song, W., Jeong, B. C., & Nam, J. K. (2024). Comparative analysis of recurrence rates between intravesical gemcitabine and bacillus Calmette–Guérin induction therapy following transurethral resection of bladder tumors in patients with intermediate- and high-risk bladder cancer: A retrospective multicenter study. Investigative and Clinical Urology, 65(3), 248. https://doi.org/10.4111/icu.20230313

Vancouver

Choi J, Kim KH, Kim HS, Yoon HS, Kim JH, Kim JW, et al. Comparative analysis of recurrence rates between intravesical gemcitabine and bacillus Calmette–Guérin induction therapy following transurethral resection of bladder tumors in patients with intermediate- and high-risk bladder cancer: A retrospective multicenter study. Investigative and Clinical Urology. 2024;65(3):248. doi:10.4111/icu.20230313

BibTeX
@article{Choi2024,
  author = {Choi, Joongwon and Kim, Kyung Hwan and Kim, Hyung Suk and Yoon, Hyun Sik and Kim, Jung Hoon and Kim, Jin Wook and Lee, Yong Seong and Choi, Se Young and Chang, In Ho and Ko, Young Hwii and Song, Wan and Jeong, Byong Chang and Nam, Jong Kil},
  title = {Comparative analysis of recurrence rates between intravesical gemcitabine and bacillus Calmette–Guérin induction therapy following transurethral resection of bladder tumors in patients with intermediate- and high-risk bladder cancer: A retrospective multicenter study},
  journal = {Investigative and Clinical Urology},
  year = {2024},
  volume = {65},
  number = {3},
  pages = {248},
  doi = {10.4111/icu.20230313}
}
Kostenlos starten →